About annovis bio inc - ANVS
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
ANVS At a Glance
Annovis Bio, Inc.
101 Lindenwood Drive
Malvern, Pennsylvania 19355
| Phone | 1-484-875-3192 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -28,854,197.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ANVS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.585 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.737 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ANVS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,606,774.625 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ANVS Liquidity
| Current Ratio | 5.799 |
| Quick Ratio | 5.799 |
| Cash Ratio | 5.373 |
ANVS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -164.847 |
| Return on Equity | -220.607 |
| Return on Total Capital | -171.229 |
| Return on Invested Capital | -220.607 |
ANVS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |